Key Points
- Dyne Therapeutics CFO Erick Lucera sold 1,448 shares on May 13 at an average price of $18.36, totaling about $26,585. The company said the sale was to cover tax withholding obligations tied to equity award vesting.
- Dyne recently beat quarterly earnings expectations, reporting a loss of $0.73 per share versus analysts’ estimate of a $0.77 loss. Analysts still expect the company to post a full-year loss of 2.96 per share.
- Wall Street sentiment remains generally positive, with HC Wainwright reiterating a Buy rating and a $50 price target, while the broader analyst consensus is Moderate Buy with a target price of $35.21.
Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) CFO Erick Lucera sold 1,448 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, May 13th. The shares were sold at an average price of $18.36, for a total value of $26,585.28. Following the sale, the chief financial officer directly owned 123,925 shares in the company, valued at approximately $2,275,263. The trade was a 1.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Dyne Therapeutics Stock Performance
Dyne Therapeutics stock opened at $18.28 on Friday. The stock's 50 day simple moving average is $18.30 and its two-hundred day simple moving average is $18.64. The company has a debt-to-equity ratio of 0.17, a quick ratio of 22.25 and a current ratio of 19.92. The stock has a market cap of $3.02 billion, a price-to-earnings ratio of -5.68 and a beta of 1.08. Dyne Therapeutics, Inc. has a fifty-two week low of $8.06 and a fifty-two week high of $25.00.
Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.73) EPS for the quarter, topping analysts' consensus estimates of ($0.77) by $0.04. During the same period in the prior year, the firm earned ($1.05) earnings per share. As a group, analysts expect that Dyne Therapeutics, Inc. will post -2.96 earnings per share for the current fiscal year.
Key Dyne Therapeutics News
Here are the key news stories impacting Dyne Therapeutics this week:
- Positive Sentiment: HC Wainwright reiterated a Buy rating and a $50 price target, while lifting several earnings forecasts for Dyne Therapeutics, signaling continued analyst confidence in the stock’s longer-term potential.
- Positive Sentiment: Lifesci Capital also increased its earnings estimates for 2026 and 2026 quarterly periods, reflecting improved expectations for Dyne Therapeutics’ financial outlook.
- Neutral Sentiment: Dyne Therapeutics said management will participate in upcoming investor conferences, which can help keep the company visible to shareholders but does not change the fundamentals by itself. Dyne Therapeutics to Participate in Upcoming Investor Conferences
- Neutral Sentiment: The company received an average brokerage rating of Moderate Buy, suggesting Wall Street sentiment remains constructive overall. Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Rating of "Moderate Buy" by Brokerages
- Negative Sentiment: CEO John Cox, CFO Erick Lucera, and insider Douglas Kerr each sold small blocks of stock, which can weigh on sentiment, although the filings say the sales were made to cover tax obligations tied to equity vesting.
Analyst Upgrades and Downgrades
DYN has been the topic of several analyst reports. Chardan Capital reaffirmed a "buy" rating and issued a $38.00 price objective on shares of Dyne Therapeutics in a research report on Monday, March 9th. Sanford C. Bernstein upped their price objective on Dyne Therapeutics from $23.00 to $24.00 and gave the company a "market perform" rating in a research report on Wednesday. Jefferies Financial Group reaffirmed a "buy" rating on shares of Dyne Therapeutics in a research report on Monday, March 9th. Morgan Stanley lowered their price objective on Dyne Therapeutics from $50.00 to $47.00 and set an "overweight" rating on the stock in a research report on Monday, March 2nd. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Dyne Therapeutics in a research report on Monday, April 20th. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Dyne Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $35.21.
View Our Latest Research Report on DYN
Institutional Investors Weigh In On Dyne Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of DYN. AQR Capital Management LLC purchased a new stake in shares of Dyne Therapeutics in the 1st quarter worth $246,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Dyne Therapeutics by 5.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,466 shares of the company's stock worth $597,000 after purchasing an additional 2,886 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Dyne Therapeutics by 58.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 994,886 shares of the company's stock worth $10,407,000 after purchasing an additional 366,183 shares in the last quarter. Caxton Associates LLP purchased a new stake in shares of Dyne Therapeutics in the 1st quarter worth $157,000. Finally, Creative Planning increased its stake in shares of Dyne Therapeutics by 23.8% in the 2nd quarter. Creative Planning now owns 14,541 shares of the company's stock worth $138,000 after purchasing an additional 2,797 shares in the last quarter. 96.68% of the stock is currently owned by hedge funds and other institutional investors.
Dyne Therapeutics Company Profile
(
Get Free Report)
Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.
Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
